Company profile
PROKIDNEY CORP.
NASDAQ:PROKBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03270956 | phase2 | completed | 2018-04-25 | 2022-11-17 | Prokidney | A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease |
| NCT05694169 | phase1 | terminated | 2023-07-11 | 2024-03-19 | Prokidney | A Study of Participants With Chronic Kidney Disease Previously Treated With REACT |
| NCT05286853 | phase3 | withdrawn | 2024-07-17 | 2024-09-03 | Prokidney | A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease |
| NCT02836574 | phase2 | completed | 2016-09-01 | 2023-12-01 | Prokidney | A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease |
| NCT04115345 | phase1 | completed | 2019-08-13 | 2023-01-31 | Prokidney | A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). |
FDA applications (0)
No records yet.